Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease (Q33361388)

26 July 2017

1 reference

title

Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease (English)

1 reference

26 July 2017

1 reference

Susan M Cheer

1

1 reference

26 July 2017

Christopher J Dunn

series ordinal

2

1 reference

26 July 2017

Rachel Foster

series ordinal

3

1 reference

26 July 2017

publication date

1 January 2004

1 reference

26 July 2017

1 reference

26 July 2017

volume

64

1 reference

26 July 2017

issue

13

1 reference

26 July 2017

page(s)

1479-1502

1 reference

New aspects on heparin and lipoprotein metabolism

26 July 2017

cites work

1 reference

12 December 2020

Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers

1 reference

12 December 2020

Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers

1 reference

12 December 2020

The epidemiology of venous thromboembolism.

1 reference

12 December 2020

Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery

1 reference

12 December 2020

Biologic tolerance of two different low molecular weight heparins

1 reference

12 December 2020

Heparin-releasable TFPI is not depleted after repeated injections of tinzaparin at therapeutic dose for up to 30 days

1 reference

12 December 2020

Low-molecular-weight heparins: are they all the same?

1 reference

12 December 2020

Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin

1 reference

12 December 2020

Formulary management of low molecular weight heparins

1 reference

12 December 2020

The outcome of ambulatory DVT management using a multidisciplinary approach

1 reference

12 December 2020

Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin

1 reference

12 December 2020

A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation

1 reference

12 December 2020

Long-term use of low molecular weight heparin ameliorates hyperlipidemia in patients on hemodialysis

1 reference

12 December 2020

Relationship between pharmacokinetics and pharmacodynamics of tinzaparin (logiparin), a low molecular weight heparin, in dogs

1 reference

12 December 2020

Low-molecular-weight heparins

1 reference

12 December 2020

Dose titration study of tinzaparin, a low molecular weight heparin, in patients on chronic hemodialysis

1 reference

12 December 2020

Low-molecular-weight heparin.

1 reference

12 December 2020

Biochemical and pharmacologic inequivalence of low molecular weight heparins

1 reference

12 December 2020

Low-Mr heparin is as potent as conventional heparin in releasing lipoprotein lipase, but is less effective in preventing hepatic clearance of the enzyme

1 reference

12 December 2020

Prevention of thromboembolism in spinal cord injury: role of low molecular weight heparin

1 reference

12 December 2020

Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin

1 reference

12 December 2020

Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers

1 reference

12 December 2020

Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders

1 reference

12 December 2020

Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis.

1 reference

12 December 2020

Is impaired renal function a contraindication to the use of low-molecular-weight heparin?

1 reference

12 December 2020

Prevention of venous thromboembolism

1 reference

12 December 2020

Early discharge and home supervision of patients with pulmonary embolism treated with low-molecular weight heparin.

1 reference

12 December 2020

Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis

1 reference

12 December 2020

The treatment of deep vein thrombosis and pulmonary embolism

1 reference

12 December 2020

Long-term use of the low molecular weight heparin tinzaparin in haemodialysis

1 reference

12 December 2020

Heparin and low molecular weight heparin: background and pharmacology

1 reference

12 December 2020

Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis

1 reference

12 December 2020

Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4)

1 reference

12 December 2020

Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis

1 reference

12 December 2020

Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients

1 reference

12 December 2020

The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects

1 reference

12 December 2020

Tinzaparin sodium for thrombosis treatment and prevention during pregnancy

1 reference

12 December 2020

Tinzaparin sodium: a low-molecular-weight heparin.

1 reference

12 December 2020

Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis.

1 reference

12 December 2020

Antithrombotic therapy for venous thromboembolic disease

1 reference

12 December 2020

Comparative study of the pharmacokinetic profiles of two LMWHs—bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)—administered subcutaneously to healthy male volunteers

1 reference

12 December 2020

Characterization of platelet binding of heparins and other glycosaminoglycans

1 reference

12 December 2020

Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study

1 reference

12 December 2020

A cross-over study of a new low molecular weight heparin (Logiparin) in hemodialysis

1 reference

12 December 2020

Cost comparison of tinzaparin versus enoxaparin as deep venous thrombosis prophylaxis in spinal cord injury: preliminary data

1 reference

12 December 2020

Effect of tissue factor pathway inhibitor (TFPI) in the HEPTEST assay and in an amidolytic anti factor Xa assay for LMW heparin

1 reference

12 December 2020

Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers.

1 reference

12 December 2020

Influence of a low molecular weight heparin on the inhibition of factor Xa and thrombin in hip surgery

1 reference

12 December 2020

Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. H.B.P.M. Research Group

1 reference

12 December 2020

Low molecular weight heparin compared with dextran as prophylaxis against thrombosis after total hip replacement

1 reference

12 December 2020

Biological tolerance of Logiparin, a low molecular weight heparin used in patients undergoing total hip replacement

1 reference

12 December 2020

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

1 reference

12 December 2020

Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective

1 reference

12 December 2020

Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis?

1 reference

12 December 2020

An international standard for low molecular weight heparin.

1 reference

12 December 2020

Treatment and prevention of venous thromboembolism.

1 reference

12 December 2020

Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo

1 reference

12 December 2020

Antimetastatic effect of tinzaparin, a low-molecular-weight heparin

1 reference

12 December 2020

Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin.

1 reference

12 December 2020

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

1 reference

12 December 2020

Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venografic controlled study

1 reference

12 December 2020

Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin

1 reference

12 December 2020

Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective

1 reference

12 December 2020

Low molecular weight heparin

1 reference

12 December 2020

Home treatment of deep vein thrombosis. An out-patient treatment model with once-daily injection of low-molecular-weight heparin (tinzaparin) in 555 patients

1 reference

12 December 2020

Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days

1 reference

12 December 2020

Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects

1 reference

12 December 2020

Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center

1 reference

12 December 2020

Low-molecular-weight heparin: prophylaxis and treatment of venous thromboembolism

1 reference

12 December 2020

Effects of conventional vs. low-molecular-weight heparin on lipid profile in hemodialysis patients.

1 reference

12 December 2020

Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery. A double-blind multicenter trial

1 reference

12 December 2020

Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty.

1 reference

12 December 2020

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

1 reference

12 December 2020

Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group

1 reference

12 December 2020

Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin.

1 reference

12 December 2020

Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage

1 reference

12 December 2020

10.2165/00003495-200464130-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1017324610

0 references

1 reference